Join to View Full Profile
12902 Usf Magnolia DrTampa, FL 33612
Phone+1 813-745-3980
Fax+1 813-745-6817
Dr. Haura is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1997 - 2000
Johns Hopkins UniversityResidency, Internal Medicine, 1994 - 1997
Duke University School of MedicineClass of 1994
Certifications & Licensure
FL State Medical License 2000 - 2027
NC State Medical License 1999 - 2001
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification FairWarning® Patient Privacy Monitoring, FairWarning Technologies, LLC, 2016
- CMS Meaningful Use Stage 1 Certification HealtheLife and PowerChart, Cerner Corporation, 2016
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2016
Clinical Trials
- Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates Start of enrollment: 2004 Oct 01
- Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2007 Mar 01
- Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation Start of enrollment: 2009 Mar 01
Publications & Presentations
PubMed
- Targeting GSTZ1 Sensitizes KRASG12C-Mutant Lung Cancer Cells by Overcoming Glutathione and Glycolysis Pathway Rewiring.Yi Liao, Xueli Li, Min Liu, Vanessa C Fernandes, Derek Duckett
Cancer Research Communications. 2026-06-01 - Multifactorial sheltering in peristromal niches shapes in vivo responses of lung cancers to targeted therapies.Bina Desai, Tatiana Miti, Sandhya Prabhakaran, Daria Miroshnychenko, Pragya Kumar
Nature Communications. 2026-05-29 - Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in-mutant non-small cell lung cancer and exploratory HER2 profiling in human tumors.Hilal Ozakinci, Bina Desai, Denise Kalos, Dung-Tsa Chen, Menkara Henry
Translational Lung Cancer Research. 2026-04-30
Press Mentions
Protein Interaction Assay May Identify Best NSCLC Candidates for KRAS G12C InhibitorsFebruary 5th, 2025- Moffitt Study Finds Key Biomarker to Predict KRASG12C Inhibitor Effectiveness in Lung CancerJanuary 31st, 2025
- Moffitt Research Identifies Crucial Biomarker for Predicting Effectiveness of KRASG12C Inhibitors in Lung Cancer TreatmentJanuary 31st, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
